Australian Prescriber

Subject Index: Australian Prescriber Volumes 17 to current (1994-2008)

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

To find a reference on this page either scroll or hold down the "Ctrl" key and press "f".

eating disorders

assessment and management 21(4) 100-3

letter 22(3) 53-4

management and patient support organisations 21(4) 105

treatment with antidepressants 28(4) 91-3

Ebixa

see memantine 26(5) 118-9

echocardiography

diagnostic tests 29(5) 134-8

letter 30(1) 3-4

perflutren - contrast medium - Definity (New drug) 30(4) 107-11

ecstasy

adverse effects 29(4) 109-11

ectoparasitic infestations

lindane toxicity (letters) 21(1) 5-8; 20(2) 31-2

pediculosis capitis (letters) 24(1) 3; 23(5) 93-6

pediculosis capitis management 23(3) 62-3

scabies management 23(2) 33-5

eczema

mometasone - Elocon (New drug) 17(1) 6-8

editorials

ACE inhibitors - clinical pharmacology in heart failure 19(1) 2-3

antibiotic resistance 22(2) 26-8

dental implications 22(2) 31

antibiotic resistance and animal husbandry 24(2) 26-7

antidepressants

costs and benefits 18(4) 82-4

suicide risk in children 28(5) 110-1; 28(5) 111-3

letter 29(2) 32-5

antineoplastics - adverse effects 23(1) 5

letter 23(3) 55-6

antiviral drugs and influenza prophylaxis 30(2) 30-1

arthritis - COX inhibitors 23(2) 26-7

asthma and inhaled corticosteroids 20(3) 54-5; 20(3) 56-7

Australian Medicines Handbook 20(1) 2-3

Australian Prescriber - outsourcing to National Prescribing Service 25(2) 26-7; 25(1) 2

Australian Prescriber internet access 21(3) 59

calcium channel antagonists and risk of myocardial infarction 22(1) 2-3; 19(2) 30-4

cardiovascular medicine in the 21st century 23(1) 2

cerebrovascular imaging 24(6) 134

chemotherapy and cancer survival rates 29(1) 2-3

children and off-label prescribing 26(6) 122-3

letter 27(2) 28-33

clinical investigations and professional indemnity 19(4) 86-7

dental implications 19(4) 97

clinical investigations and professional negligence 19(4) 87-8

Cochrane Airways Group 24(4) 78-9

competency for non-medical prescribers 30(3) 58-9

complementary medicines safety 25(3) 50-1

letter 26(2) 27-9

consumer information 26(1) 2-3

consumer product information 19(2) 30-4

cost effectiveness of drugs 19(3) 58-9

cost of drugs and drug industry profits 26(2) 26-7

letter 26(3) 51-2

depression in medical illness 30(4) 86-8

direct-to-consumer advertising in New Zealand (editorial) 29(2) 30-2

donepezil in Alzheimer's disease 28(6) 134-5

letter 29(3) 59-62

drug advertising and consumers 22(4) 74-5

drug advertising and the media 23(4) 70-1

letter 23(6) 115-7

drug information - independent drug bulletins 25(1) 3-4

letter 25(3) 51-3

drug patent evergreening 29(6) 148-9

drug prescribing in general practice 23(6) 114-5; 23(3) 51

letter 23(5) 93-6

drug regulatory secrecy 25(4) 78-9

comments 25(6) 130-1; 25(5) 103-4

drug therapy for children in the 21st century 23(1) 3

drugs in sport 17(4) 78-9

letters 18(3) 56-7

economic analysis and the drug industry 22(3) 50-1

effectiveness of new drugs 27(1) 2-3

letter 27(3) 55-7

electronic prescribing in hospitals 24(1) 2-3

letter 24(4) 80-2

evidence-based medicine - turning knowledge into action 30(5) 114-5

expensive drugs and the Pharmaceutical Benefits Scheme 29(6) 146-8

letter 30(3) 59-63

expensive medical technology 17(3) 54-5

letters 18(2) 27-9

expensive new drugs 27(6) 136-7; 27(6) 137-8

letter 28(3) 55-8

flucloxacillin vs other antibiotics 18(3) 54-6

letter 19(1) 3-6

freedom of publication of drug evaluations 29(5) 120

letters 30(2) 32-4

gabapentin promotion and off-label prescribing (editorial comment) 26(1) 19

letters 26(3) 51-2; 26(2) 27-9

general practice in the 21st century 23(1) 4

HMG CoA reductase inhibitors and myocardial infarction 21(4) 86-7

hormone replacement therapy 23(5) 90-2

hospital discharge - medication information and prescriptions 29(3) 58-9

letters 29(5) 121

hypertension management - consensus conference 17(2) 26-7

intensive management of diabetes 25(5) 102-3

letter 26(1) 3-4

menopause 17(1) 2-4

National Prescribing Service 21(2) 30-1

NSAIDS and cardiovascular disease in rheumatology 29(4) 90-1

nurse prescribing 30(1) 2-3

letters 31(1) 3-4; 30(4) 88-90

osteoporosis consensus conference 20(4) 82-3

letter 21(2) 31-4

palliative care - non-malignant disease 26(5) 98-9

Pharmaceutical Benefits Scheme drug price reforms 30(6) 138-40

Pharmaceutical Benefits Scheme economic evaluation 25(6) 126-7

polypharmacy 31(1) 2-3

the polypill and cardiovascular disease 28(4) 82-3

prescriber feedback 21(1) 2-3

prescribing and older persons 22(6) 130-1

prescribing and the law 27(5) 108-9

letters 28(2) 29-33; 28(2) 29-33

prescribing budgets 20(2) 28-9; 20(2) 30-1

letters 20(4) 83-6

prescribing costs 20(2) 26-7

prostatic hypertrophy - drug costs and benefits 18(2) 26-7

letter 19(1) 3-6

psychiatry in the 21st century 23(1) 4

quality use of generic drugs 27(4) 80-1

letters 28(2) 29-33; 27(6) 138-41

quality use of medicines 24(5) 106-7; 21(3) 58-9

letters 22(2) 28-31; 22(1) 3-5

safety and withdrawal of COX inhibitors 28(3) 54-5

salmeterol - safety concerns 29(5) 118-9

selective serotonin reuptake inhibitors and suicide risk in children 28(5) 111-3

letter 29(2) 32-5

statins and muscle damage 26(4) 74-5

therapeutic guidelines 24(3) 50-1

thiazide diuretics in hypertension 22(5) 102-3

geriatrics in the 21st century 23(1) 3

tramadol adverse effects 27(2) 26-7

transparency of information about new drugs (editorial) 28(4) 83-4

US Free Trade Agreement and pharmaceuticals 27(3) 54-5

letter 27(5) 109-13

withdrawal of drugs from market 26(3) 50-1

letters 27(2) 28-33; 26(5) 99-102

Edronax

see reboxetine 25(5) 120-3

efalizumab

Raptiva - psoriasis (New drug) 28(1) 19-23

efavirenz - HIV

Stocrin (New drug) 22(6) 147-51

Stocrin (New strength) 25(6) 147-51

Efexor

see venlafaxine 22(1) 20-3; 19(3) 81-3

eflornithine hydrochloride

Vaniqa - facial hair reduction (New drug) 29(3) 84-7

eformoterol

in asthma 21(1) 22-4

asthma - Foradile (New drug) 20(2) 45-51

combination inhalers in asthma 28(2) 26-8

elderly (see also aged)

infusion pumps 18(2) 49-51

electrocardiography

'Pocket guide to ECGs' (book review) 29(4) 93

electronic prescribing (see also drug information; drug utilisation)

advertising in clinical software 23(3) 52-3

in general practice (editorials) 23(3) 50-1; 23(3) 51

in general practice (letters) 24(4) 80-2; 23(5) 93-6

in hospitals (editorial) 24(1) 2-3

letter 24(4) 80-2

Electronic Therapeutic Guidelines

CD review 25(3) 53

Elidel

see pimecrolimus 27(2) 28-33; 26(6) 146-51

Eligard

see leuprorelin 27(2) 50-1

Elmiron

see pentosan polysulphate sodium 17(3) 73

Elocon

see mometasone 17(1) 6-8

Eloxatin

see oxaliplatin 24(5) 107-9; 24(3) 71-5

Emend

see aprepitant 27(3) 76-9

emergencies

MedicAlert (letter) 18(4) 84-6

emergency medicine

Australian Medicines Handbook - book review 28(2) 41; 24(3) 55

dental pain in general practice 24(6) 144-8

letter - aminophylline for asthma 20(3) 57-60

emergency supplies

emergency drugs - doctor's bag supplies 30(6) 143-6; 19(4) 89-92

adenosine, activated charcoal and verapamil (PBAC question) 20(4) 86-7

emergency drugs in dentistry 30(6) 146

triple antigen in doctor's bag (PBAC question) 19(3) 75

EMLA Patch

see lignocaine 17(4) 87-90

emtricitabine

Emtriva - HIV infection (New drug) 28(2) 49-51

Emtriva

see emtricitabine 28(2) 49-51

Enablex - see darifenacin hydrobromide

enalapril maleate

Alphapril (New brand) 24(2) 43-7

Enalapril-BC (New brand) 24(4) 100-2

hydrochlorothiazide (New combination) 24(1) 20-3

enantiomers

pharmacology and efficacy 27(2) 47-9

correction 28(3) 55-8

letter 27(5) 109-13

Enbrel

see etanercept 25(1) 20-3

endocarditis

antibiotic guidelines (letter) 24(3) 51-5

antibiotics in prophylaxis 20(1) 11

letter 20(3) 57-60

in dentistry (letters) 21(2) 31-4

endocrinology

Therapeutic Guidelines - book review 28(3) 58; 24(6) 148

endometrial cancer

risks and hormone replacement therapy 23(5) 90-2

endometriosis

gestrinone - Dimetriose (New drug) 19(1) 24-7

nafarelin - Synarel (New drug) 17(2) 30-2

endoscopy

management of gastrointestinal haemorrhage 28(3) 62-6

enfuvirtide

Fuzeon - HIV infection (New drug) 27(6) 159-65

England - National Health Service

prescriber feedback (editorial) 21(1) 3-4

enoxacin

quinoline antibiotic - Enoxin (New drug) 18(1) 7-9

enoxaparin

in thromboembolism 19(4) 104-8

Enoxin

see enoxacin 18(1) 7-9

entacapone

in Parkinson's disease 24(4) 92-5

Parkinson's disease - Comtan (New drug) 22(6) 147-51

entecavir

Baraclude - chronic hepatitis B (New drug) 29(5) 138-43

Entocort

enzyme replacement - alglucerase - Gaucher's disease - Ceredase (New drug) 18(1) 7-9

imiglucerase - Gaucher's disease - Cerezyme (New drug) 22(4) 95-8

see budesonide 22(1) 20-3

eosinophilia

clinical pharmacology of corticosteroids in asthma 19(2) 44-7

Epaq inhaler

see salbutamol 24(2) 43-7

epidemics

see disease outbreaks 30(2) 30-1; 25(3) 51-3

epilepsy

Australian Pregnancy Register 23(2) 43

clinical use of antiepileptics 17(1) 9-12

drugs which lower seizure threshold 24(1) 8-9

letters 24(5) 107-9; 24(3) 51-5

fosphenytoin - Pro-Epanutin (New drug) 23(5) 110-1

gabapentin - Neurontin (New drug) 17(3) 73

lamotrigine - Lamictal (New drug) 17(1) 6-8

levetiracetam - Keppra (New drug) 24(4) 100-2

new antiepileptic drugs 22(3) 61-3

oxcarbazepine - Trileptal (New drug) 25(1) 20-3

patient support organisations 21(2) 39

positron emission tomography 18(1) 15-8

pregabalin - Lyrica (New drug) 28(3) 75-9

rectal diazepam in children 21(2) 35-6

tiagabine - Gabitril (New drug) 21(1) 25-7

topiramate - Topamax (New drug) 21(3) 80-3

withdrawal of antiepileptic drugs in seizure-free adults 27(5) 114-7

withdrawal of drugs from seizure-free children 29(1) 18-21

EpiPen

see adrenaline 29(2) 52-3; 28(4) 90

epirubicin

epirubicin injection (New brand) 25(6) 147-51

eplerenone

Inspra - heart failure postmyocardial infarction (New drug) 28(5) 130-1

letter 29(2) 32-5

epoetin alfa

Eprex (New formulation) 24(3) 71-5; 22(5) 125-7

Eprex (New strength) 23(3) 64-7

epoetin beta

NeoRecormon - anaemia (New drug) 29(4) 112-5

epoprostenol

primary pulmonary hypertension - Flolan (New drug) 25(6) 147-51

Eprex

see epoetin alfa 24(3) 71-5; 23(3) 64-7; 22(5) 125-7

eprosartan mesylate

antihypertensive - Teveten (New drug) 23(4) 84-7

hydrochlorothiazide - Teveten Plus (New combination) 25(6) 147-51

eptifibatide

coronary disease - Integrilin (New drug) 26(6) 146-51

Erbitux

see cetuximab 28(4) 104-6

erectile dysfunction

alprostadil - Caverject (New strength) 22(2) 43-7; 18(3) 58-9

alprostadil - MUSE (New formulation) 22(2) 43-7

management 21(2) 46-8

sildenafil - Viagra (New drug) 21(4) 108-11

tadalafil - Cialis (New drug) 26(2) 46-7

vardenafil - Levitra (New drug) 26(3) 68-71

Ergamisol

see levamisole 20(2) 45-51

ergoline derivatives

cabergoline - hyperprolactinaemia - Dostinex (New drug) 19(1) 24-7

ventricular tachycardia 18(1) 18

letter 18(2) 27-9

erlotinib

Tarceva - non-small cell lung cancer (New drug) 29(2) 53-5

Erotab

see fluoxetine 22(4) 95-8

ertapenem

antibiotic - Invanz (New drug) 25(4) 94-9

erythema nodosum leprosum

thalidomide - Thalidomide Pharmion (New drug) 26(6) 146-51

erythrocyte sedimentation rate

C-reactive protein - abnormal laboratory results 30(3) 74-6

erythropoietin

epoetin beta - NeoRecormon - anaemia (New drug) 29(4) 112-5

escitalopram oxalate

antidepressant - Lexapro (New drug) 26(6) 146-51

letter 27(2) 28-33

chiral drugs - pharmacology and efficacy 27(2) 47-9

Esmeron

see rocuronium bromide 18(4) 86-7

esomeprazole

chiral drugs - pharmacology and efficacy 27(2) 47-9

gastrointestinal haemorrhage (letter) 28(6) 136-9

Nexium IV (New formulation) 27(6) 159-65

peptic ulcer, gastro-oesophageal reflux - Nexium (New drug) 25(4) 94-9

Estalis

see oestradiol/norethisterone acetate 23(5) 110-1

Estracombi

see oestradiol and oestradiol norethisterone combination 19(2) 38-40

etanercept

Enbrel (New drug) 25(1) 20-3

rheumatoid arthritis 27(2) 43-6

tumour necrosis factor blockers in rheumatology 29(3) 67-70

eTG complete

CD review 25(3) 53

ethics

communication of risk 26(2) 44-5

drug promotion and health professionals 30(6) 150-3

of gene therapy 20(3) 72-3

of prescribing (letter) 24(2) 27-8; 23(5) 93-6

ethinyloestradiol

cyproterone combination - new brand - Brenda-35 ED 20(1) 22-3

dienogest combination - contraceptive - Valette (New drug) 30(2) 50-55

drospirenone combination - contraceptive - Yasmin (New drug) 25(6) 147-51

gestodene combination - Femoden, Trioden, Minulet, Triminulet (New drug) 18(1) 7-9

ethosuximide

clinical use of antiepileptics 17(1) 9-12

Ethyol

see amifostine 20(1) 22-3

etidronate

osteoporosis 23(6) 133-6

etonogestrol

contraceptive - Implanon (New drug) 24(2) 43-7

Etopophos

see etoposide 24(3) 71-5

etoposide

Etopophos (New strength) 24(3) 71-5

etretinate metabolite

acitretin - psoriasis and keratinisation disorders - Neotigason (New drug) 18(4) 86-7

evergreening

drug patents (editorial) 29(6) 148-9

everolimus

Certican - transplantation (New drug) 28(3) 75-9

pharmacology of immunosuppressants 29(4) 99-101

evidence-based medicine

appraising medical research 29(5) 122-4

editorial 24(3) 50-1

hormone replacement therapy advice to patients 25(3) 60-2

letters 25(5) 104-7

information services 24(5) 116-9

letters 25(4) 79-80; 25(1) 4

online information services and general practice 27(1) 16-8

pharmacotherapy for risk factors 30(2) 47-50

letter 30(4) 88-90

turning knowledge into action (editorial) 30(5) 114-5

Evista

see raloxifene 22(4) 95-8

Exelon

see rivastigmine 23(5) 110-1

exemestane

breast cancer - Aromasin (New drug) 24(3) 71-5

exenatide

type 2 diabetes - Byetta (New drug) 30(6) 163-7

exercise

back pain 17(2) 33-6

diabetes 30(5) 130-3

letter 31(1) 3-4

osteoarthritis 18(1) 2-4

letter 18(4) 84-6

exercise testing

diabetes 30(5) 130-3

letter 31(1) 3-4

thallium scanning in coronary disease 17(3) 57-61

Exjade

see deferasirox 29(4) 112-5

experimental pharmacology - see pharmacology

expiry dates

drug 17(2) 46-8

extended-release products 22(4) 88-90

eye - see also specific diseases

eye drops, correct use 31(1) 16-17

ocular toxoplasmosis 25(4) 88-90

letter 26(3) 51-2

eye infections

letters 18(2) 27-9

management 17(3) 66-8

eye of Horus

Australian Prescriber cover design 18(1) 23

letters 19(4) 92-3; 19(2) 36-8; 18(4) 84-6

ezetimibe

hypercholesterolaemia - Ezetrol (New drug) 26(6) 146-51

RADAR comment 27(5) 128

Ezetrol

see ezetimibe 27(5) 128; 26(6) 146-51

Home

Useful Links

Privacy

Web Manager



	Home About Us Contact Us Index Search Consumer Topics Back Issues